{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:37:00Z","timestamp":1786718220221,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/ijp.ijp_304_16","type":"journal-article","created":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T05:36:52Z","timestamp":1506490612000},"page":"223","source":"Crossref","is-referenced-by-count":9,"title":["Adverse drug reaction monitoring in patients on antiretroviral therapy in a tertiary care hospital in Eastern India"],"prefix":"10.4103","volume":"49","author":[{"given":"Shatavisa","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Era","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibhuti","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SantanuKumar","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.215726-1","unstructured":"Factsheet 2015. UNAIDS. Accessed from: http:\/\/www.unaids.org\/en\/resources\/campaigns\/HowAIDSchangedeverything\/factsheet. [Last accessed on 2016 May 21]."},{"key":"key-10.4103\/0253-7613.215726-2","first-page":"125","volume-title":"A turning point: The new world health organization guidelines for treatment of human immunodeficiency virus infection","author":"Kulkarni","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/0253-7613.215726-3","first-page":"390","volume-title":"Antiretroviral drugs in the treatment of people living with human immunodeficiency virus: Experience in a South Indian tertiary referral centre","author":"Kumarasamy","year":"2000","journal-title":"J Assoc Physicians India"},{"key":"key-10.4103\/0253-7613.215726-4","first-page":"87","volume-title":"Adverse drug reactions of highly active antiretroviral therapy (HAART) in HIV infected patients at the general hospital, Douala, Cameroon: A cross sectional study","author":"Namme","year":"2012","journal-title":"Pan Afr Med J"},{"key":"key-10.4103\/0253-7613.215726-5","first-page":"257","volume-title":"Early versus standard antiretroviral therapy for HIV-infected adults in Haiti","author":"Severe","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.215726-6","first-page":"236","volume-title":"Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study.Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group","author":"Bonfanti","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.4103\/0253-7613.215726-7","first-page":"75","volume-title":"Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy","author":"Dean","year":"2002","journal-title":"AIDS"},{"key":"key-10.4103\/0253-7613.215726-8","first-page":"239","volume-title":"A method for estimating the probability of adverse drug reactions","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.4103\/0253-7613.215726-9","unstructured":"The use of the WHO-UMC System for Standardised Case Causality Assessment. Available from: http:\/\/www.who-umc.org\/Graphics\/24734.pdf. [Last accessed on 2016 May 21]."},{"key":"key-10.4103\/0253-7613.215726-10","first-page":"2229","volume-title":"Preventability and severity assessment in reporting adverse drug reactions","author":"Hartwig","year":"1992","journal-title":"Am J Hosp Pharm"},{"key":"key-10.4103\/0253-7613.215726-11","first-page":"e515","volume-title":"Current scenario of HIV\/AIDS, treatment options, and major challenges with compliance to antiretroviral therapy","author":"Bhatti","year":"2016","journal-title":"Cureus"},{"key":"key-10.4103\/0253-7613.215726-12","first-page":"125","volume-title":"Antiretroviral pre-exposure prophylaxis: A new opportunity to slow HIV spread in India","author":"Mayer","year":"2016","journal-title":"Indian J Med Res","ISSN":"https:\/\/id.crossref.org\/issn\/0971-5916","issn-type":"print"},{"key":"key-10.4103\/0253-7613.215726-13","first-page":"555","volume-title":"Survival outcomes for first-line antiretroviral therapy in India's ART program","author":"Dandona","year":"2016","journal-title":"BMC Infect Dis"},{"key":"key-10.4103\/0253-7613.215726-14","first-page":"221","volume-title":"Comparative efficacy of nucleoside\/nucleotide reverse transcriptase inhibitors in combination with efavirenz: Results of a systematic overview","author":"Bartlett","year":"2007","journal-title":"HIV Clin Trials"},{"key":"key-10.4103\/0253-7613.215726-15","first-page":"558","volume-title":"Factors associated with efavirenz discontinuation in a large community-based sample of patients","author":"Spire","year":"2004","journal-title":"AIDS Care"},{"key":"key-10.4103\/0253-7613.215726-16","first-page":"1201\u20131215","volume-title":"Neurologic and psychiatric complications of antiretroviral agents","author":"Treisman","year":"2002","journal-title":"AIDS"},{"key":"key-10.4103\/0253-7613.215726-17","first-page":"585","volume-title":"Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study","author":"Young","year":"2005","journal-title":"Antivir Ther"},{"key":"key-10.4103\/0253-7613.215726-18","first-page":"334","volume-title":"Liver enzymes elevation and immune reconstitution among treatment-na\u00efve HIV-infected patients instituting antiretroviral therapy","author":"Ofotokun","year":"2007","journal-title":"Am J Med Sci"},{"key":"key-10.4103\/0253-7613.215726-19","first-page":"56","volume-title":"Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs","author":"da","year":"2015","journal-title":"World J Virol"},{"key":"key-10.4103\/0253-7613.215726-20","first-page":"1073","volume-title":"Hematopoietic growth factors as adjuncts to antiretroviral therapy","author":"Miles","year":"1992","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key-10.4103\/0253-7613.215726-21","first-page":"S500","volume-title":"Zidovudine intolerance","author":"Groopman","year":"1990","journal-title":"Rev Infect Dis"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:32:29Z","timestamp":1786714349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_304_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"alternative-id":["215726"],"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_304_16","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}